FFO
HRMY icon

Fortitude Family Office’s Harmony Biosciences HRMY Stock Holding History

Fortitude Family Office’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5
Closed -$138 – 2010
2025
Q3 		$138 Hold
5
– – ﹤0.01% 1943
2025
Q2 		$158 Buy
+5
New +$161 ﹤0.01% 1977

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fortitude Family Office's HRMY Position: Q4 2025 in Review

Fortitude Family Office sold out of Harmony Biosciences (HRMY) in Q4 2025, closing a stake of 5 shares — an estimated $138 sold.

Fortitude Family Office first reported a position in HRMY in Q2 2025 and held it in 2 quarters. The position peaked at $158 in Q2 2025. 323 funds tracked by Wall St. Rank hold HRMY as of Q4 2025.

  • Fortitude Family Office reported no remaining Harmony Biosciences position as of Q4 2025 after selling out during the quarter.
  • Fortitude Family Office sold 5 Harmony Biosciences shares in Q4 2025, an estimated $138.
  • Fortitude Family Office first reported a position in Harmony Biosciences in Q2 2025 and held it in 2 quarters.
  • Fortitude Family Office's Harmony Biosciences position peaked at $158 in Q2 2025.
  • 323 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2025.

Based on Fortitude Family Office's 13F filing for Q4 2025, filed 15 Jan 2026.